Observational studyMedicine2025
Prognostic difference of molecular subtypes in non-muscle invasive bladder cancer.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, 2 molecular types have been defined in urothelial carcinoma, as luminal and basal. The molecular subtyping is generally based on genetic studies in non-muscle invasive bladder cancer (NMIBC) however the studies with immunohistochemical reflection of this subtyping in NMIBC is limited. In our study, we aimed to use GATA3 and keratin 5/6 for subtyping of NMIBC, and to investigate the follow-up results. Materials and methods: Patients who underwent transurethral resection for the first time and whose final diagnosis was reported as NMIBC were prospectively included. A block representing the tumor was stained with GATA3 and keratin 5/6.The relationships between the subtypes and demographic data, recurrence rates, and time to recurrence were evaluated. A total of 100 patients diagnosed with NMIBC were included. The keratin 5/6 negativity was 64% and all of these patients were GATA3 positive. The keratin 5/6 positivity was 36%. None of the age, tumor size, lamina propria invasion, keratin 5/6 and GATA3 positivity were significant for predicting the risk of recurrence. The mean time to recurrence was 283 days and 332 days in the keratin 5/6 positive and negative group, respectively but the relation was not statistically significant. Molecular classification is difficult due to technical reasons, but it can be performed with GATA3 and keratin 5/6 by immunohistochemistry. New studies are needed to determine the clinical differences and to specialize the management of bladder tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.